Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
US6338848B1 · kind B1 · utility
45Cited by
14References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2000 |
| Grant date | Jan 15, 2002 |
| Priority date | — |
| Expiry date | Feb 25, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.